Seamus Fernandez
Stock Analyst at Guggenheim
(2.27)
# 914
Out of 5,343 analysts
113
Total ratings
48.21%
Success rate
33.80%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CDTX Cidara Therapeutics | Maintains: Strong Buy | 35 50 | 25.83 | 93.57% | 3 | May 16, 2025 | |
LLY Eli Lilly | Maintains: Buy | 973 928 | 715.22 | 29.75% | 13 | Apr 14, 2025 | |
MBX MBX Biosciences | Reiterates: Buy | 44 44 | 12.55 | 250.6% | 2 | Apr 10, 2025 | |
ARQT Arcutis Biotherapeut... | Reiterates: Buy | n/a | n/a | n/a | 3 | Apr 3, 2025 | |
VERV Verve Therapeutics | Reiterates: Buy | n/a | n/a | n/a | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 160 160 | 33.98 | 370.87% | 4 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 56 | 28.05 | 99.64% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | n/a | n/a | n/a | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | n/a | n/a | n/a | 7 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 137 130 | 77.83 | 67.03% | 11 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 62.08 | 12.76% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 16 | 6.15 | 160.16% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | n/a | n/a | 1 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | n/a | n/a | n/a | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 50 | 24.66 | 102.76% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 65 | n/a | n/a | 1 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 8 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | n/a | n/a | n/a | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 2 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 48 75 | n/a | n/a | 5 | Dec 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 27 | n/a | n/a | 3 | Nov 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 220 | n/a | n/a | 6 | Nov 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 56 54 | 1.27 | 4151.97% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 60 45 | 20.4 | 120.59% | 2 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 36 38 | 69.93 | -45.66% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Market Perform | 35 38 | 23.01 | 65.15% | 3 | Jan 31, 2018 |